<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Biophysical profile test for antepartum fetal assessment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Biophysical profile test for antepartum fetal assessment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Biophysical profile test for antepartum fetal assessment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Frank A Manning, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynn L Simpson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vanessa A Barss, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The fetal biophysical profile (BPP) is a noninvasive, easily learned and performed antepartum test for evaluating fetal well-being. Ultrasound is used to assess four discrete biophysical parameters: fetal movement, fetal tone, fetal breathing, and amniotic fluid volume. A separate nonstress test of the fetal heart rate (FHR) can also be performed as a component of the BPP. Each of the four ultrasound parameters and the nonstress test are assigned a score of either 0 or 2 points (there is no 1 point), depending upon whether specific criteria are met  (<a class="graphic graphic_table graphicRef79813" href="/d/graphic/79813.html" rel="external">table 1</a>). A total score ≥8 is a strong indicator that fetal oxygen levels and acid-base status are normal and the fetal brain is well perfused and oxygenated, whereas a score ≤4 can be a sign of fetal compromise. Ideally, identification of a compromised fetus will make it possible for the provider to perform interventions (often delivery) that prevent adverse fetal/neonatal sequelae. </p><p>The five biophysical parameters were chosen based upon their ease of measurement and the ability to evaluate them objectively using universally available equipment. Other fetal biophysical activities (eg, sucking, eye movements, swallowing, micturition) might serve equally well as markers of fetal health but are not included in the BPP because measurement is more difficult and assessment may be subjective.</p><p>Three fundamental principles guide the interpretation and application of the BPP score: </p><p class="bulletIndent1"><span class="glyph">●</span>Acute fetal biophysical variables do not occur randomly; they are regulated by functional regulatory centers in the fetal brain. The output of the regulatory centers is sensitive to normal modulation by fetal sleep-wake cycles and suppression by pathologic conditions such as hypoxemia and acidemia. The sensitivity to suppression from hypoxemia or acidemia varies by regulatory center, a phenomenon described as the "gradual hypoxia concept." </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Amniotic fluid volume is a chronic variable and can be independent of acute variables. Oligohydramnios usually takes time to evolve (assuming normal kidneys, patent urinary tract, and intact membranes) and is often a consequence of fetal adaptation to chronic hypoxemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The BPP score needs to be interpreted within the clinical setting, which includes gestational age/risk of neonatal mortality and morbidity associated with early delivery  (<a class="graphic graphic_figure graphicRef78999" href="/d/graphic/78999.html" rel="external">figure 1</a>), potentially treatable fetal conditions, and the maternal condition. The object is to manage the patient, not the test.</p><p></p><p>This topic will review issues related to the BPP. An overview of antenatal fetal surveillance and detailed information on the nonstress test and the contraction stress test are available separately. (See  <a class="medical medical_review" href="/d/html/457.html" rel="external">"Overview of antepartum fetal assessment"</a> and  <a class="medical medical_review" href="/d/html/409.html" rel="external">"Nonstress test and contraction stress test"</a>.)</p><p class="headingAnchor" id="H437906459"><span class="h1">INDICATIONS</span><span class="headingEndMark"> — </span>Antepartum fetal assessment with tests such as the BPP is indicated for pregnancies in the mid- to late-second and the third trimesters at increased risk of fetal demise. Specific conditions and clinical settings that are considered indications for antenatal fetal assessment are discussed separately, but the decision is ultimately based on the clinical judgment of the provider. (See  <a class="medical medical_review" href="/d/html/457.html" rel="external">"Overview of antepartum fetal assessment", section on 'Indications for fetal assessment'</a>.)</p><p>Although the BPP is typically used for antepartum fetal assessment, it can also be performed intrapartum; however, its clinical utility in the intrapartum setting is unclear [<a href="#rid1">1,2</a>].</p><p class="headingAnchor" id="H2"><span class="h1">PHYSIOLOGIC BASIS OF THE BIOPHYSICAL PROFILE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The four 'acute' parameters</strong> – Four of the five BPP parameters reflect acute fetal status: fetal breathing movements, generalized fetal movements, fetal tone, and fetal heart rate (FHR) accelerations in response to fetal movements (nonstress test). All of these fetal biophysical activities are regulated by discrete centers in the brain that are sensitive to both local factors and feedback from peripheral sensors. The fall in oxygen concentration necessary to affect the output of a specific central nervous system (CNS) regulatory center and thereby reduce fetal oxygen requirements varies by the regulatory center.</p><p></p><p class="bulletIndent1">The two most oxygen-sensitive centers are the cardioregulatory neurons, which control FHR acceleration, and the fetal breathing center neurons, which control fetal breathing movements. Even mild hypoxemia can lead to reductions in these biophysical parameters. Fetal movement has a higher threshold before being affected by hypoxemia and fetal tone center has the highest threshold. As a result of the different sensitivities to hypoxemia, fetal biophysical activities respond to hypoxemia in a predictable, physiologically based cascade: loss of FHR accelerations and fetal breathing movements, followed by decreased fetal movement, and finally loss of fetal tone. This sequence is informative clinically since it allows for estimation of both the presence and severity of hypoxemia [<a href="#rid3">3,4</a>]. </p><p></p><p class="bulletIndent1">In a lamb model, the CNS regulatory centers were sensitive to modulation by sleep-wake cycles and noxious stimuli (eg, hypoxemia, acidemia) when studied at the human equivalent of approximately 26 weeks of gestation [<a href="#rid5">5</a>]. Although CNS regulatory centers have not been studied systematically before the human equivalent of 26 weeks, it seems likely that the ability of sleep-wake cycles and noxious stimuli to modulate the biophysical activities controlled by these centers would occur at the same time or shortly after developmental emergence of the biophysical activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The single 'chronic' parameter</strong> – Amniotic fluid volume, the fifth parameter, is not an acute parameter since decreases in amniotic fluid volume in response to chronic uteroplacental insufficiency generally occur gradually. On average, in the absence of membrane rupture, it takes approximately 15 days for amniotic fluid volume to progress from normal to reduced and 23 days to progress to severe oligohydramnios [<a href="#rid6">6</a>]. However, acute changes in amniotic fluid volume and rapid deterioration of the BPP score have been reported [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Fetal urine is the predominant source of amniotic fluid after approximately 16 weeks of gestation. It depends primarily upon renal perfusion, which in turn reflects selective distribution of cardiac output. The fetus responds to sustained hypoxemia by selective redistribution of its cardiac output, with preferential flow directed to the brain, heart, adrenals, and placenta at the expense of all other organ systems [<a href="#rid8">8</a>]. This protective mechanism is initiated by specialized chemoreceptors in the aortic arch and carotid arteries. Hypoxemia-induced reflex redistribution of cardiac output away from the kidneys results in diminished fetal urine production, ultimately leading to oligohydramnios and then anhydramnios [<a href="#rid6">6</a>]. Theoretically, a decrease in fetal swallowing, which removes amniotic fluid, could compensate for the decrease in urine production, but fetal swallowing is a vegetative reflex that is very resistant to the effects of hypoxemia. (See  <a class="medical medical_review" href="/d/html/2283.html" rel="external">"Physiology of amniotic fluid volume regulation"</a>.)</p><p></p><p class="bulletIndent1">Scoring for excessive amniotic fluid volume is not part of the BPP because hypoxia is not one of the many diverse etiologies for this finding.</p><p></p><p class="headingAnchor" id="H6"><span class="h1">DETERMINING THE BIOPHYSICAL PROFILE SCORE</span></p><p class="headingAnchor" id="H2732876210"><span class="h2">Assigning points</span><span class="headingEndMark"> — </span>Each of the five parameters in the composite BPP score has been evaluated independently and the normal characteristic defined  (<a class="graphic graphic_table graphicRef79813" href="/d/graphic/79813.html" rel="external">table 1</a>) [<a href="#rid9">9</a>] (see <a class="local">'Physiologic basis of the biophysical profile'</a> above). The scoring method used for each parameter is binary (ie, the parameter is either normal or abnormal; gradations of abnormality are not used). A normal parameter is assigned a score of 2 and an abnormal parameter is assigned a score of 0. The maximum score is 10/10 and the minimum score is 0/10.</p><p>When assigning points, the clinician should be aware of some pitfalls. Decoupling of the CNS regulatory centers from the neurons generating a specific biophysical activity occasionally occurs and can result in pathological conditions that should not be confused with normal biophysical activity. For example [<a href="#rid10">10-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Fetal breathing activity characterized by a very regular rate and excursion depth that is continuous and without apneic intervals ("picket-fence breathing") or gasping (slow intermittent excursions) should not be considered normal breathing movements.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Seizures should not be counted as normal fetal limb movements.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sinusoidal fetal heart rate (FHR) pattern on the nonstress test should not be confused with normal long-term variability.</p><p></p><p class="headingAnchor" id="H972105269"><span class="h2">Duration of fetal observation</span><span class="headingEndMark"> — </span>A parameter may be assigned a normal score (2) as soon as it is observed. Because the acute parameters are subject to fetal sleep-wake cycles, the fetus should be observed continuously for at least 30 minutes before assigning 0 points for any acute parameter. This time is based on ultrasound studies of fetuses from uncomplicated pregnancies. In one such study at 36 to 42 weeks of gestation, the mean duration of a fetal sleep (no somatic movements) was approximately 20 minutes, with an upper range of approximately 40 minutes [<a href="#rid13">13</a>].</p><p>The average time to obtain a normal BPP score (BPP 8/8) is 5.3 minutes, and the test can be stopped at that point. When all tests are considered (normal, equivocal, abnormal), the average testing time is approximately 18 minutes [<a href="#rid14">14</a>]. Fetal acoustic stimulation can decrease testing time [<a href="#rid15">15,16</a>]. Some caution in interpreting fetal biophysical responses to acoustic stimulation seems prudent since intense stimulation and particularly painful stimulation can overcome the suppressive effects of hypoxemia/acidemia. The effectiveness of maternal glucose administration and change in position to shorten the average time to complete a BPP score has not been formally evaluated and is unproven.</p><p class="headingAnchor" id="H437905353"><span class="h2">Use of the nonstress test</span><span class="headingEndMark"> — </span>A BPP of 8/8 as derived from the ultrasound variables alone without a nonstress test has the same high predictive accuracy as a BPP of 10/10 when a reactive nonstress test is included because the central nervous system (CNS) center regulating the interaction between fetal movement and FHR accelerations and the CNS center regulating fetal breathing movements have very similar sensitivity to hypoxia and acidemia. Thus, a reactive nonstress test or presence of fetal breathing movements, either alone or in combination, are equally good predictors of normal oxygenation of these regulatory centers [<a href="#rid17">17</a>]. The decision to add a nonstress test result to a BPP of 8/8 (ultrasound variables only) is a matter of clinician personal preference. An advantage of including the nonstress test is fetal arrhythmias and cord compression patterns (variable decelerations) are more readily detected. The disadvantage is extended testing time. We always include a nonstress test as part of the composite BPP when one or more acute variables is abnormal or oligohydramnios is identified, or when abnormalities such as fetal growth restriction or abnormal Doppler velocimetry are present.</p><p>A BPP of 8/10, where the absent variable is either a nonreactive nonstress test or absent fetal breathing movements, has the same high predictive accuracy of fetal well-being. In a prospective clinical study in which the nonstress test was only performed if one of the ultrasound variables (usually fetal breathing movements) was absent, a nonstress test was needed in less than 3 percent of tests and this approach reduced average testing time without reducing the predictive value of the BPP [<a href="#rid17">17</a>]. In a retrospective study of 3981 BPP tests among 985 high-risk pregnancies, the positive and negative predictive accuracy of an ultrasound variable-only BPP and a full BPP (including the nonstress test) were comparable [<a href="#rid18">18</a>].</p><p>Rarely, a nonstress test will be persistently nonreactive on serial testing. The most likely explanation is coincidence of sleep-wake cycles. However, the possibility of an intrinsic error in the integration of proprioceptor signals or expression of cardiac regulation is another possibility. If the ultrasound variables remain normal, then intervention based on a repetitive nonreactive nonstress test result is not necessary.</p><p class="headingAnchor" id="H3364235843"><span class="h1">ALTERNATIVES</span></p><p class="headingAnchor" id="H437905424"><span class="h2">Modified biophysical profile</span><span class="headingEndMark"> — </span>The modified BPP was developed to simplify the examination and reduce the time necessary to complete testing by focusing on those components of the BPP that are most predictive of outcome: nonstress test and amniotic fluid volume. Assessment of both the nonstress test and amniotic fluid volume appears to be as reliable a predictor of long-term fetal well-being as the full (ie, five component) BPP [<a href="#rid19">19,20</a>]. The rate of stillbirth within one week of a normal modified BPP is the same as with the full BPP: 0.8 per 1000 patients tested [<a href="#rid20">20</a>].</p><p>Approximately 90 percent of pregnancies that undergo a modified BPP will have a normal result; the remainder will need to proceed to a full biophysical evaluation.</p><p class="headingAnchor" id="H2320609587"><span class="h1">TESTING SCHEDULE</span></p><p class="headingAnchor" id="H1354688055"><span class="h2">Initiation</span><span class="headingEndMark"> — </span>Testing should begin as soon as an increased risk of fetal demise is identified and delivery for perinatal benefit would be considered if test results are abnormal. This may be as early as 22 weeks of gestation [<a href="#rid21">21</a>], but is more commonly by 32 to 36 weeks. Determining the gestational age to begin testing is discussed in more detail separately. (See  <a class="medical medical_review" href="/d/html/13511.html" rel="external">"Periviable birth (limit of viability)"</a> and  <a class="medical medical_review" href="/d/html/457.html" rel="external">"Overview of antepartum fetal assessment", section on 'Timing'</a>.)</p><p class="headingAnchor" id="H290409843"><span class="h2">Frequency</span><span class="headingEndMark"> — </span>As a general rule, a normal BPP score predicts fetal well-being for up to a week, so testing is commonly repeated weekly until delivery as long as the indication for testing persists and appears to be stable [<a href="#rid22">22,23</a>]. However, the type and severity of the clinical situation needs to be considered (ie, manage the patient, not the test) and thus varies from weekly, to two or more times per week, to daily, and even to multiple times daily. In particular, any significant deterioration in the clinical condition (eg, worsening preeclampsia, recurrent antepartum hemorrhage, poorly controlled diabetes) or decreased fetal activity requires reevaluation, regardless of the amount of time elapsed since the last test. For example, a severely growth-restricted fetus with absent or reversed Doppler velocimetry of the umbilical artery and oligohydramnios can quickly deteriorate from a BPP of 8/10 to a BPP of 2/10 [<a href="#rid21">21,24,25</a>]. (See  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome"</a>.)</p><p class="headingAnchor" id="H302709940"><span class="h1">INTERPRETATION</span><span class="headingEndMark"> — </span>As a general rule, the more variables that are absent, the more likely the absence is due to a pathologic rather than a physiologic cause. An acute variable(s) can be absent for any of the following reasons: </p><p class="bulletIndent1"><span class="glyph">●</span>Hypoxemia and acidemia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A deep stage of fetal quiet sleep, which is a benign physiological etiology. Fetal breathing is most affected by quiet sleep, fetal movement less so, and fetal tone is affected only at the deepest stages of quiet sleep [<a href="#rid13">13</a>]. Extending the time for BPP generally eliminates uncertainly between physiologic and pathologic etiologies since the fetus is likely to have at least one active (REM) cycle in a 30-minute period.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transplacental passage of a substance that causes general suppression of brain activity, such as a sedative, opioid, or alcohol.</p><p></p><p>Amniotic fluid volume can be decreased in response to chronic uteroplacental insufficiency, but also from prelabor rupture of membranes or a fetal upper or lower urinary tract anomaly that interferes with urination.</p><p class="headingAnchor" id="H1108775889"><span class="h2">The normal score (10/10, 8/8, or 8/10)</span><span class="headingEndMark"> — </span>A BPP of 10/10, 8/8, or 8/10 with normal amniotic fluid volume is a normal score, a powerful predictor of normal fetal acid-base status, and associated with a very low risk of fetal death within a week (false-negative death rate 0.8 per 1000). Fetal death within a week of a normal BPP score is usually the result of an acute complication such as abruption, fetomaternal hemorrhage, cord compression, or exacerbation of maternal disease (eg, eclampsia or ketoacidosis).</p><p class="headingAnchor" id="H501631399"><span class="h3">8/10 because of oligohydramnios</span><span class="headingEndMark"> — </span>Oligohydramnios as the only abnormal variable in a BPP score is a rare finding in the absence of membrane rupture or fetal urinary tract anomaly, but may occur in postterm pregnancies and pregnancies complicated by fetal growth restriction. Management of oligohydramnios depends on the clinical scenario. (See  <a class="medical medical_review" href="/d/html/6749.html" rel="external">"Postterm pregnancy"</a> and  <a class="medical medical_review" href="/d/html/139556.html" rel="external">"Fetal growth restriction: Pregnancy management and outcome", section on 'General approach to timing'</a> and  <a class="medical medical_review" href="/d/html/6777.html" rel="external">"Oligohydramnios: Etiology, diagnosis, and management in singleton gestations"</a>.)</p><p class="headingAnchor" id="H3701808404"><span class="h2">The very abnormal score and abnormal score (0/10, 2/10, 4/10)</span></p><p class="bulletIndent1"><span class="glyph">●</span>A BPP of 0/10 is a fetal emergency and carries an extremely high risk of fetal death (600 per 1000 within seven days). A score of 0/10 is virtually always an indication for prompt delivery if the gestational age is sufficiently advanced to sustain extrauterine life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A BPP of 2/10 is very abnormal and associated with a high risk of fetal death within a week (125 per 1000 within seven days) and is virtually always an indication for prompt delivery if the gestational age is sufficiently advanced to sustain extrauterine life. </p><p></p><p class="bulletIndent1">In the extremely immature fetus (&lt;28 weeks) with this score, extending the testing time or repeat testing over a short interval (four to six hours) is a consideration. A sustained or persistent BPP of 2/10 is virtually always an indication for prompt delivery if the gestational age is sufficiently advanced to sustain extrauterine life.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A BPP of 4/10 is also very abnormal and associated with a risk of fetal death of 91 per 1000 within seven days. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oligohydramnios – In a fetus with intact membranes and a functional patent genitourinary tract, a score of 4/10 with oligohydramnios is usually an indication for delivery if the gestational age is sufficiently advanced to sustain extrauterine life. Before 34 weeks of gestation, it is reasonable to administer a course of antenatal corticosteroids and wait 24 to 48 hours before delivering the fetus, as long as the fetus remains under intense and often continuous fetal heart rate (FHR) surveillance. In the setting of membrane rupture or congenital anomalies that reduce urination, management must be individualized.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal amniotic fluid – A score of 4/10 with normal amniotic fluid is usually an indication for delivery if the gestational age is sufficiently advanced to sustain extrauterine life. Before 34 weeks of gestation, it is reasonable to administer a course of antenatal corticosteroids and repeat the BPP 24 hours after the previous BPP; delivery is indicated if the repeat BPP is 6/10 or less.</p><p></p><p class="headingAnchor" id="H3788362876"><span class="h2">Interim score (6/8)</span><span class="headingEndMark"> — </span>A BPP of 6/8 is not an acceptable final BPP result. A nonstress test always needs to be performed to determine whether this interim score will change to 6/10 or 8/10. Interpretation and management depend on this final score. (See <a class="local">'The normal score (10/10, 8/8, or 8/10)'</a> above and <a class="local">'8/10 because of oligohydramnios'</a> above and <a class="local">'The equivocal score (6/10)'</a> below.)</p><p class="headingAnchor" id="H4182525921"><span class="h2">The equivocal score (6/10)</span><span class="headingEndMark"> — </span>A BPP of 6/10 is equivocal. </p><p class="bulletIndent1"><span class="glyph">●</span>A BPP of 6/10 with oligohydramnios as one of the abnormal variables combined with any one abnormal acute variable (most commonly a nonreactive nonstress test or absent fetal breathing) is a concerning finding and is associated with a risk of fetal death of 89 per 1000 within seven days. Delivery for fetal indications is generally recommended if the gestational age is sufficiently advanced to sustain extrauterine life. In the setting of membrane rupture or fetal urinary tract abnormally, management must be individualized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A BPP of 6/10 with normal amniotic fluid volume is a truly equivocal result. In about two-thirds of cases, a repeat BPP within 24 hours will yield a normal result. Management is based upon the repeat result. If the BPP of 6/10 persists, delivery may be indicated if the gestational age is sufficiently advanced to sustain extrauterine life; management of these cases needs to be individualized. If the BPP score reverts to normal, then continued serial surveillance is appropriate.</p><p></p><p class="headingAnchor" id="H351730455"><span class="h1">FACTORS POTENTIALLY AFFECTING THE SCORE</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antenatal corticosteroids</strong> – Administration of antenatal corticosteroids can be associated with transient fetal heart rate (FHR) and behavioral changes, but these changes typically return to baseline by day 4 after treatment [<a href="#rid26">26</a>]. The most consistent change is a decrease in FHR variability on days 2 and 3 after administration [<a href="#rid27">27-31</a>]. Fetal breathing and body movements are also commonly reduced, which may result in a lower BPP score or nonreactive nonstress test [<a href="#rid31">31-34</a>]. These findings should be considered within the total clinical scenario when considering delivery because of a nonreassuring fetal evaluation (nonstress test or BPP) after corticosteroid administration.</p><p></p><p class="bulletIndent1">The behavioral changes may reflect a physiologic response of the brain to glucocorticoids. Alternatively, they may be a consequence of a transient increase in fetal vascular resistance and blood pressure, which has been demonstrated in animal studies. Fetal blood flow velocity waveform patterns in the umbilical artery, middle cerebral artery, and ductus venosus do not appear to be affected [<a href="#rid33">33,35,36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subclinical infection</strong> – The effect of subclinical infection on test results is controversial. Although intraamniotic infection in a patient with preterm prelabor rupture of membranes may be associated with a low BPP score in the absence of hypoxemia [<a href="#rid37">37</a>], most studies have found that the BPP score is an insensitive method for detecting subclinical infection [<a href="#rid38">38-41</a>]. (See  <a class="medical medical_review" href="/d/html/120959.html" rel="external">"Preterm prelabor rupture of membranes: Management and outcome", section on 'Fetal monitoring'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preterm labor</strong> – Preterm labor may be associated with absence of fetal breathing movements, but absence of fetal breathing movements is not a good predictor of preterm delivery within 48 hours or seven days [<a href="#rid42">42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fasting</strong> – There are sparse data on the effect of fasting on fetal biophysical activities. A study that performed a BPP one hour after a meal and 10 to 12 hours after abstaining from food and drink in 30 patients with uncomplicated pregnancies reported scores were ≥8/10 for all postprandial BPPs, but two fasting BPPs were 4/10 and 6/10; both increased to 10/10 after the mother ate a meal [<a href="#rid43">43</a>]. Point reductions during fasting were primarily due to nonreactive nonstress tests and inadequate fetal breathing movements.</p><p></p><p class="bulletIndent1">It is difficult to draw any conclusion about the effect of fasting on the BPP score in the clinical setting, given the small size of this study and the absence of indications for antepartum fetal assessment. Some clinicians give the patient juice or another type of food/drink if a BPP shows inadequate breathing or the nonstress test is nonreactive. However, a meta-analysis found that maternal glucose administration did not significantly decrease the incidence of nonreactive test results related to quiet fetal sleep; the effect on BPP scores was not evaluated [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Mild maternal anemia does not appear to affect fetal biophysical activities [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H2684541522"><span class="h1">EVIDENCE OF EFFICACY</span><span class="headingEndMark"> — </span>Although the use of biophysical testing schemes to monitor high-risk pregnancies has become routine, this practice pattern has evolved with limited high-quality scientific evidence to support its use [<a href="#rid46">46</a>]. Moreover, there are no randomized trials on which to base recommendations for the best initial testing approach for specific types of high-risk pregnancies, the optimal timing of test initiation, the frequency of testing based on test results, conditions that may affect test results, and the effect of gestational age.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Meta-analysis of randomized trials</strong> – In a meta-analysis of randomized trials comparing BPP with conventional fetal heart rate (FHR) monitoring (five trials involving 2974 high risk pregnancies), use of the BPP did not reduce perinatal death (relative risk [RR] 1.33, 95% CI 0.60-2.98) or the frequency of low Apgar scores (RR 1.27, 95% CI 0.85-1.92) [<a href="#rid47">47</a>]. Three of the trials were of low quality; the two higher-quality studies were small (n = 280 high-risk pregnancies) and results did not exclude the possibility of a small or modest benefit. Conventional FHR monitoring included the nonstress test, contraction stress test, and modified BPP. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Observational studies</strong> – Observational studies have reported the BPP is accurate for predicting the absence of significant fetal acidemia [<a href="#rid48">48</a>] and comparable to the contraction stress test [<a href="#rid49">49</a>]. For example, in one observational study including almost 45,000 BPPs, the risk of fetal demise within one week of a normal test result was 0.8 per 1000 pregnant individuals tested (corrected for lethal congenital anomalies and unpredictable causes of demise) [<a href="#rid50">50</a>]. This result compares favorably with all other means of antepartum fetal assessment. In two observational studies including over 18,000 pregnant individuals, use of the BPP was associated with a 61 to 76 percent reduction in perinatal mortality (corrected) compared with historic controls [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1">In other observational studies, as the last BPP score fell  (<a class="graphic graphic_figure graphicRef78661" href="/d/graphic/78661.html" rel="external">figure 2</a>), perinatal mortality (gross and corrected) and serious perinatal morbidity (nonreassuring FHR pattern in labor, low Apgar scores, neonatal seizures, admission to an intensive care unit, hypoxemic-ischemic encephalopathy, intrauterine growth restriction) increased significantly [<a href="#rid52">52,53</a>]. In addition, the cord blood pH of newborns delivered either vaginally or by cesarean had a direct relationship to the last BPP score  (<a class="graphic graphic_figure graphicRef65562" href="/d/graphic/65562.html" rel="external">figure 3</a>) [<a href="#rid54">54</a>]. An inverse relationship between last BPP score and incidence of cerebral palsy has also been observed and may be related to antepartum asphyxia  (<a class="graphic graphic_figure graphicRef54595" href="/d/graphic/54595.html" rel="external">figure 4</a>). Long-term asphyxia leading to adverse neurologic outcomes such as cerebral palsy and intellectual disability appears to be significantly reduced in high-risk patients managed by fetal BPP scoring compared with untested low-risk patients [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Physiologic data</strong> – The advent of ultrasound-guided intrauterine fetal blood sampling (cordocentesis) made it possible to measure the direct and immediate relationship between the BPP score, fetal PO<sub>2</sub>, and fetal pH [<a href="#rid3">3,56</a>]. These studies, which include over 1000 paired observations, reported a direct relationship between the BPP score and mean umbilical venous pH and suggest that, in the individual fetus, the BPP score accurately predicts both the probability and severity of existing acidemia [<a href="#rid57">57,58</a>]. Thus, the score appears to be an accurate proxy for fetal acidosis. In contrast, the relationship between the BPP score and fetal PO<sub>2</sub> is less precise, which is expected since PO<sub>2</sub> varies according to fetal compensatory adaptive responses.</p><p></p><p class="headingAnchor" id="H437906117"><span class="h1">ROUTE OF DELIVERY AFTER A LOW BIOPHYSICAL PROFILE SCORE</span><span class="headingEndMark"> — </span>The route of delivery is an obstetric decision based on multiple variables including presentation, cervical findings, and maternal and fetal condition. In the absence of an obstetric contraindication, induction of labor with continuous intrapartum fetal heart monitoring is a reasonable option for most patients, regardless of BPP score. The positive predictive value of a low BPP score for intrapartum fetal compromise (eg, a nonreassuring fetal heart tracing, neonatal acidemia, or other markers of neonatal morbidity at the time of delivery) is approximately 50 percent, with a negative predictive value greater than 99.9 percent.</p><p class="headingAnchor" id="H3938005198"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/126123.html" rel="external">"Society guideline links: Fetal surveillance"</a>.)</p><p class="headingAnchor" id="H455947132"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gestational age</strong> – The minimum gestational age for initiating biophysical testing should reflect the lower limit that delivery would be considered for an abnormal test, which is typically 22 weeks. (See <a class="local">'Initiation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scoring</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Assigning points</strong> – The five fetal parameters used for determining the biophysical profile (BPP) score are heart rate accelerations in response to movement (nonstress test), breathing movement, body and limb movement, tone, and amniotic fluid volume, as described in the table  (<a class="graphic graphic_table graphicRef79813" href="/d/graphic/79813.html" rel="external">table 1</a>). (See <a class="local">'Assigning points'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duration of observation</strong> – A parameter may be assigned a normal score as soon as it is observed. The acute parameters (movement, tone, breathing) are subject to fetal sleep-wake cycles; therefore, the fetus should be observed continuously for at least 30 minutes before the parameter is assigned 0 points. A BPP cannot be scored as abnormal if the testing time is less than 30 minutes. (See <a class="local">'Duration of fetal observation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of the nonstress test</strong> – A BPP of 8/8 has the same high predictive accuracy of fetal well-being as a BPP of 10/10 (ie, when a reactive nonstress test is included). A nonstress test can be omitted if the BPP score is 8/8 after ultrasound alone but should always be performed if any ultrasound monitored parameter is 0. (See <a class="local">'Use of the nonstress test'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Interpretation</strong> –<strong> </strong>The general approach to interpretation of the BPP score is shown in the table  (<a class="graphic graphic_table graphicRef141378" href="/d/graphic/141378.html" rel="external">table 2</a>). However, the BPP score always needs to be interpreted within the clinical setting, which includes gestational age/risk of neonatal mortality and morbidity associated with early delivery, potentially treatable fetal conditions, and the maternal condition. The object is to manage the patient, not the test.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Frequency of testing</strong> – The type and severity of the clinical situation needs to be considered and thus varies from weekly, to two or more times per week, to daily, and even to multiple times daily. Any significant deterioration in the clinical condition (eg, worsening preeclampsia, recurrent antepartum hemorrhage, poorly controlled diabetes) or decreased fetal activity requires reevaluation, regardless of the amount of time elapsed since the last test. (See <a class="local">'Frequency'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance</strong> – In observational studies, use of the BPP score as part of the management of high-risk obstetric patients has been associated with a significant reduction in perinatal mortality. However, randomized trials have not established superiority of the full (ie, five component) BPP compared with cardiotocography or the modified BPP (nonstress test plus amniotic fluid volume). (See <a class="local">'Evidence of efficacy'</a> above and <a class="local">'Modified biophysical profile'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kim SY, Khandelwal M, Gaughan JP, et al. Is the intrapartum biophysical profile useful? Obstet Gynecol 2003; 102:471.</a></li><li><a class="nounderline abstract_t">Sassoon DA, Castro LC, Davis JL, et al. The biophysical profile in labor. Obstet Gynecol 1990; 76:360.</a></li><li><a class="nounderline abstract_t">Manning FA, Snijders R, Harman CR, et al. Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH. Am J Obstet Gynecol 1993; 169:755.</a></li><li><a class="nounderline abstract_t">Vintzileos AM, Lettieri L, Tsapanos V, et al.. Relationship Between Combined Fetal Biophysical Activities, Oligohydramnios, and Fetal Acid–Base Status. J Matern Fetal Med 1994; 3:64.</a></li><li><a class="nounderline abstract_t">Clewlow F, Dawes GS, Johnston BM, Walker DW. Changes in breathing, electrocortical and muscle activity in unanaesthetized fetal lambs with age. J Physiol 1983; 341:463.</a></li><li><a class="nounderline abstract_t">Nicolaides KH, Peters MT, Vyas S, et al. Relation of rate of urine production to oxygen tension in small-for-gestational-age fetuses. Am J Obstet Gynecol 1990; 162:387.</a></li><li><a class="nounderline abstract_t">Sherer DM, Dayal AK, Schwartz BM, et al. Acute oligohydramnios and deteriorating fetal biophysical profile associated with severe preeclampsia. J Matern Fetal Med 1999; 8:193.</a></li><li><a class="nounderline abstract_t">Cohn HE, Sacks EJ, Heymann MA, Rudolph AM. Cardiovascular responses to hypoxemia and acidemia in fetal lambs. Am J Obstet Gynecol 1974; 120:817.</a></li><li><a class="nounderline abstract_t">Manning FA, Platt LD, Sipos L. Antepartum fetal evaluation: development of a fetal biophysical profile. Am J Obstet Gynecol 1980; 136:787.</a></li><li><a class="nounderline abstract_t">Patrick JE, Dalton KJ, Dawes GS. Breathing patterns before death in fetal lambs. Am J Obstet Gynecol 1976; 125:73.</a></li><li><a class="nounderline abstract_t">Manning FA, Martin CB Jr, Murata Y, et al. Breathing movements before death in the primate fetus (Macaca mulatta). Am J Obstet Gynecol 1979; 135:71.</a></li><li><a class="nounderline abstract_t">Romero R, Chervenak FA, Berkowitz RL, Hobbins JC. Intrauterine fetal tachypnea. Am J Obstet Gynecol 1982; 144:356.</a></li><li><a class="nounderline abstract_t">Pillai M, James D. Behavioural states in normal mature human fetuses. Arch Dis Child 1990; 65:39.</a></li><li><a class="nounderline abstract_t">Manning FA, Baskett TF, Morrison I, Lange I. Fetal biophysical profile scoring: a prospective study in 1,184 high-risk patients. Am J Obstet Gynecol 1981; 140:289.</a></li><li><a class="nounderline abstract_t">Papadopoulos VG, Decavalas GO, Kondakis XG, Beratis NG. Vibroacoustic stimulation in abnormal biophysical profile: verification of facilitation of fetal well-being. Early Hum Dev 2007; 83:191.</a></li><li><a class="nounderline abstract_t">Pinette MG, Blackstone J, Wax JR, Cartin A. Using fetal acoustic stimulation to shorten the biophysical profile. J Clin Ultrasound 2005; 33:223.</a></li><li><a class="nounderline abstract_t">Manning FA, Morrison I, Lange IR, et al. Fetal biophysical profile scoring: selective use of the nonstress test. Am J Obstet Gynecol 1987; 156:709.</a></li><li><a class="nounderline abstract_t">Zafman KB, Bruck E, Rebarber A, et al. Antenatal Testing for Women With Preexisting Medical Conditions Using Only the Ultrasonographic Portion of the Biophysical Profile. Obstet Gynecol 2018; 132:1033.</a></li><li><a class="nounderline abstract_t">Nageotte MP, Towers CV, Asrat T, Freeman RK. Perinatal outcome with the modified biophysical profile. Am J Obstet Gynecol 1994; 170:1672.</a></li><li><a class="nounderline abstract_t">Miller DA, Rabello YA, Paul RH. The modified biophysical profile: antepartum testing in the 1990s. Am J Obstet Gynecol 1996; 174:812.</a></li><li><a class="nounderline abstract_t">Baschat AA, Galan HL, Lee W, et al. The role of the fetal biophysical profile in the management of fetal growth restriction. Am J Obstet Gynecol 2022; 226:475.</a></li><li><a class="nounderline abstract_t">Manning FA, Harman CR, Morrison I, et al. Fetal assessment based on fetal biophysical profile scoring. IV. An analysis of perinatal morbidity and mortality. Am J Obstet Gynecol 1990; 162:703.</a></li><li><a class="nounderline abstract_t">Dayal AK, Manning FA, Berck DJ, et al. Fetal death after normal biophysical profile score: An eighteen-year experience. Am J Obstet Gynecol 1999; 181:1231.</a></li><li><a class="nounderline abstract_t">Manning FA. Dynamic ultrasound-based fetal assessment: the fetal biophysical profile score. Clin Obstet Gynecol 1995; 38:26.</a></li><li><a class="nounderline abstract_t">Kaur S, Picconi JL, Chadha R, et al. Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh &lt;1000 g. Am J Obstet Gynecol 2008; 199:264.e1.</a></li><li><a class="nounderline abstract_t">Verdurmen KM, Renckens J, van Laar JO, Oei SG. The influence of corticosteroids on fetal heart rate variability: a systematic review of the literature. Obstet Gynecol Surv 2013; 68:811.</a></li><li><a class="nounderline abstract_t">Subtil D, Tiberghien P, Devos P, et al. Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone. Am J Obstet Gynecol 2003; 188:524.</a></li><li><a class="nounderline abstract_t">Mulder EJ, Derks JB, Visser GH. Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone. Br J Obstet Gynaecol 1997; 104:1239.</a></li><li><a class="nounderline abstract_t">Senat MV, Minoui S, Multon O, et al. Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study. Br J Obstet Gynaecol 1998; 105:749.</a></li><li><a class="nounderline abstract_t">Rotmensch S, Liberati M, Vishne TH, et al. The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial. Acta Obstet Gynecol Scand 1999; 78:493.</a></li><li><a class="nounderline abstract_t">Rotmensch S, Lev S, Kovo M, et al. Effect of betamethasone administration on fetal heart rate tracing: a blinded longitudinal study. Fetal Diagn Ther 2005; 20:371.</a></li><li><a class="nounderline abstract_t">Kelly MK, Schneider EP, Petrikovsky BM, Lesser ML. Effect of antenatal steroid administration on the fetal biophysical profile. J Clin Ultrasound 2000; 28:224.</a></li><li><a class="nounderline abstract_t">Rotmensch S, Liberati M, Celentano C, et al. The effect of betamethasone on fetal biophysical activities and Doppler velocimetry of umbilical and middle cerebral arteries. Acta Obstet Gynecol Scand 1999; 78:768.</a></li><li><a class="nounderline abstract_t">Katz M, Meizner I, Holcberg G, et al. Reduction or cessation of fetal movements after administration of steroids for enhancement of lung maturation. I. Clinical evaluation. Isr J Med Sci 1988; 24:5.</a></li><li><a class="nounderline abstract_t">Deren O, Karaer C, Onderoglu L, et al. The effect of steroids on the biophysical profile and Doppler indices of umbilical and middle cerebral arteries in healthy preterm fetuses. Eur J Obstet Gynecol Reprod Biol 2001; 99:72.</a></li><li><a class="nounderline abstract_t">Derks JB, Giussani DA, Jenkins SL, et al. A comparative study of cardiovascular, endocrine and behavioural effects of betamethasone and dexamethasone administration to fetal sheep. J Physiol 1997; 499 ( Pt 1):217.</a></li><li><a class="nounderline abstract_t">Vintzileos AM. Antepartum surveillance in preterm rupture of membranes. J Perinat Med 1996; 24:319.</a></li><li><a class="nounderline abstract_t">Lewis DF, Adair CD, Weeks JW, et al. A randomized clinical trial of daily nonstress testing versus biophysical profile in the management of preterm premature rupture of membranes. Am J Obstet Gynecol 1999; 181:1495.</a></li><li><a class="nounderline abstract_t">Ghidini A, Salafia CM, Kirn V, et al. Biophysical profile in predicting acute ascending infection in preterm rupture of membranes before 32 weeks. Obstet Gynecol 2000; 96:201.</a></li><li><a class="nounderline abstract_t">Del Valle GO, Joffe GM, Izquierdo LA, et al. The biophysical profile and the nonstress test: poor predictors of chorioamnionitis and fetal infection in prolonged preterm premature rupture of membranes. Obstet Gynecol 1992; 80:106.</a></li><li><a class="nounderline abstract_t">Gauthier DW, Meyer WJ, Bieniarz A. Biophysical profile as a predictor of amniotic fluid culture results. Obstet Gynecol 1992; 80:102.</a></li><li><a class="nounderline abstract_t">Honest H, Bachmann LM, Sengupta R, et al. Accuracy of absence of fetal breathing movements in predicting preterm birth: a systematic review. Ultrasound Obstet Gynecol 2004; 24:94.</a></li><li><a class="nounderline abstract_t">Tug N, Ayvaci H, Tarhan N, et al. Effects of short-term maternal fasting in the third trimester of pregnancy on fetal biophysical profile and Doppler indices scores. Arch Gynecol Obstet 2011; 283:461.</a></li><li><a class="nounderline abstract_t">Tan KH, Sabapathy A. Maternal glucose administration for facilitating tests of fetal wellbeing. Cochrane Database Syst Rev 2012; :CD003397.</a></li><li><a class="nounderline abstract_t">Nomura RM, Gordon MC, Fatobene G, et al. [Effects of maternal anemia on computerized cardiotocography and fetal biophysical profile]. Rev Bras Ginecol Obstet 2009; 31:615.</a></li><li><a class="nounderline abstract_t">Signore C, Freeman RK, Spong CY. Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop. Obstet Gynecol 2009; 113:687.</a></li><li><a class="nounderline abstract_t">Lalor JG, Fawole B, Alfirevic Z, Devane D. Biophysical profile for fetal assessment in high risk pregnancies. Cochrane Database Syst Rev 2008; :CD000038.</a></li><li><a class="nounderline abstract_t">Gribbin C, James D. Assessing fetal health. Best Pract Res Clin Obstet Gynaecol 2004; 18:411.</a></li><li><a class="nounderline abstract_t">Nageotte MP, Towers CV, Asrat T, et al. The value of a negative antepartum test: contraction stress test and modified biophysical profile. Obstet Gynecol 1994; 84:231.</a></li><li><a class="nounderline abstract_t">Manning FA, Morrison I, Harman CR, et al. Fetal assessment based on fetal biophysical profile scoring: experience in 19,221 referred high-risk pregnancies. II. An analysis of false-negative fetal deaths. Am J Obstet Gynecol 1987; 157:880.</a></li><li><a class="nounderline abstract_t">Manning FA. Fetal biophysical profile: a critical appraisal. Clin Obstet Gynecol 2002; 45:975.</a></li><li><a class="nounderline abstract_t">Manning FA, Morrison I, Lange IR, et al. Fetal assessment based on fetal biophysical profile scoring: experience in 12,620 referred high-risk pregnancies. I. Perinatal mortality by frequency and etiology. Am J Obstet Gynecol 1985; 151:343.</a></li><li><a class="nounderline abstract_t">Manning FA. Fetal biophysical profile. Obstet Gynecol Clin North Am 1999; 26:557.</a></li><li><a class="nounderline abstract_t">Vintzileos AM, Fleming AD, Scorza WE, et al. Relationship between fetal biophysical activities and umbilical cord blood gas values. Am J Obstet Gynecol 1991; 165:707.</a></li><li><a class="nounderline abstract_t">Manning FA, Bondaji N, Harman CR, et al. Fetal assessment based on fetal biophysical profile scoring. VIII. The incidence of cerebral palsy in tested and untested perinates. Am J Obstet Gynecol 1998; 178:696.</a></li><li><a class="nounderline abstract_t">Ribbert LS, Snijders RJ, Nicolaides KH, Visser GH. Relationship of fetal biophysical profile and blood gas values at cordocentesis in severely growth-retarded fetuses. Am J Obstet Gynecol 1990; 163:569.</a></li><li><a class="nounderline abstract_t">Chamberlain PF, Manning FA, Morrison I, et al. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. Am J Obstet Gynecol 1984; 150:245.</a></li><li><a class="nounderline abstract_t">Phelan JP, Ahn MO, Smith CV, et al. Amniotic fluid index measurements during pregnancy. J Reprod Med 1987; 32:601.</a></li></ol></div><div id="topicVersionRevision">Topic 5392 Version 35.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12962926" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Is the intrapartum biophysical profile useful?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2381614" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The biophysical profile in labor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8238129" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Fetal biophysical profile score. VI. Correlation with antepartum umbilical venous fetal pH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Relationship Between Combined Fetal Biophysical Activities, Oligohydramnios, and Fetal Acid–Base Status</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6413680" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Changes in breathing, electrocortical and muscle activity in unanaesthetized fetal lambs with age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2309821" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Relation of rate of urine production to oxygen tension in small-for-gestational-age fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10406305" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute oligohydramnios and deteriorating fetal biophysical profile associated with severe preeclampsia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4429091" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cardiovascular responses to hypoxemia and acidemia in fetal lambs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7355965" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antepartum fetal evaluation: development of a fetal biophysical profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5894" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Breathing patterns before death in fetal lambs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/38667" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Breathing movements before death in the primate fetus (Macaca mulatta).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7124849" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Intrauterine fetal tachypnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306133" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Behavioural states in normal mature human fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7246630" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Fetal biophysical profile scoring: a prospective study in 1,184 high-risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16860496" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Vibroacoustic stimulation in abnormal biophysical profile: verification of facilitation of fetal well-being.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16047387" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Using fetal acoustic stimulation to shorten the biophysical profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3548386" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Fetal biophysical profile scoring: selective use of the nonstress test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30130352" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Antenatal Testing for Women With Preexisting Medical Conditions Using Only the Ultrasonographic Portion of the Biophysical Profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8203424" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Perinatal outcome with the modified biophysical profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8633648" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The modified biophysical profile: antepartum testing in the 1990s.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35369904" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The role of the fetal biophysical profile in the management of fetal growth restriction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2316574" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Fetal assessment based on fetal biophysical profile scoring. IV. An analysis of perinatal morbidity and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10561651" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Fetal death after normal biophysical profile score: An eighteen-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7796550" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Dynamic ultrasound-based fetal assessment: the fetal biophysical profile score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771977" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Biophysical profile in the treatment of intrauterine growth-restricted fetuses who weigh&lt;1000 g.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25102018" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The influence of corticosteroids on fetal heart rate variability: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12592266" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Immediate and delayed effects of antenatal corticosteroids on fetal heart rate: a randomized trial that compares betamethasone acetate and phosphate, betamethasone phosphate, and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386023" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Antenatal corticosteroid therapy and fetal behaviour: a randomised study of the effects of betamethasone and dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9692416" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of dexamethasone and betamethasone on fetal heart rate variability in preterm labour: a randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10376858" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The effect of betamethasone and dexamethasone on fetal heart rate patterns and biophysical activities. A prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16113556" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effect of betamethasone administration on fetal heart rate tracing: a blinded longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10800000" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effect of antenatal steroid administration on the fetal biophysical profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10535338" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The effect of betamethasone on fetal biophysical activities and Doppler velocimetry of umbilical and middle cerebral arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3346151" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Reduction or cessation of fetal movements after administration of steroids for enhancement of lung maturation. I. Clinical evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11604189" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The effect of steroids on the biophysical profile and Doppler indices of umbilical and middle cerebral arteries in healthy preterm fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9061651" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A comparative study of cardiovascular, endocrine and behavioural effects of betamethasone and dexamethasone administration to fetal sheep.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8880628" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antepartum surveillance in preterm rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601934" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A randomized clinical trial of daily nonstress testing versus biophysical profile in the management of preterm premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10908763" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Biophysical profile in predicting acute ascending infection in preterm rupture of membranes before 32 weeks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1603478" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The biophysical profile and the nonstress test: poor predictors of chorioamnionitis and fetal infection in prolonged preterm premature rupture of membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1603477" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Biophysical profile as a predictor of amniotic fluid culture results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15229924" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Accuracy of absence of fetal breathing movements in predicting preterm birth: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20151142" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of short-term maternal fasting in the third trimester of pregnancy on fetal biophysical profile and Doppler indices scores.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972062" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Maternal glucose administration for facilitating tests of fetal wellbeing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20101377" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : [Effects of maternal anemia on computerized cardiotocography and fetal biophysical profile].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19300336" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18253968" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Biophysical profile for fetal assessment in high risk pregnancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15183136" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Assessing fetal health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8041536" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The value of a negative antepartum test: contraction stress test and modified biophysical profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3674161" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Fetal assessment based on fetal biophysical profile scoring: experience in 19,221 referred high-risk pregnancies. II. An analysis of false-negative fetal deaths.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438875" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Fetal biophysical profile: a critical appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3881967" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fetal assessment based on fetal biophysical profile scoring: experience in 12,620 referred high-risk pregnancies. I. Perinatal mortality by frequency and etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10587955" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fetal biophysical profile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1822963" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Relationship between fetal biophysical activities and umbilical cord blood gas values.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9579431" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Fetal assessment based on fetal biophysical profile scoring. VIII. The incidence of cerebral palsy in tested and untested perinates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2386143" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Relationship of fetal biophysical profile and blood gas values at cordocentesis in severely growth-retarded fetuses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6385713" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3309290" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Amniotic fluid index measurements during pregnancy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
